



S-217622 | CoV-2 M^{pro}

reversible SARS-CoV-2 3CLpro inhibitor
Ph. II/III candidate for COVID-19
virtual + HTS MS screen, SBDD
bioRxiv
Shionogi Pharmaceutical




asundexian | factor XI

factor XI inhibitor
Ph. II candidate for CV (fibrillation, stroke, MI)
related to previous series
Br. J. Clin. Pharmacol.
Bayer AG




compound 1 | CD33 pre-mRNA

CD33 splicing modulator
preclinical (neurodegeneration)
from 3.1M compd phenotypic CD33 splicing screen
ACS Med. Chem. Lett.
Pfizer Inc.




GSK3640254 | HIV Gag

HIV maturation inhibitor
Ph. II candidate for HIV
from prior clinical candidate
Antimicrob. Agents Chemother.
ViiV Healthcare (GSK)




ADU-S100 | STING

STING agonist
Ph. II candidate for met. H&N cancer
from SBDD of endogenous ligand
Clin. Cancer Res.
Aduro (Chinook Therapeutics)




MRTX1719 | PRMT5-MTA

PRMT5 inhibitor
preclinical (MTAP-deleted cancers)
from fragment-based design + SBDD
J. Med. Chem.
Mirati Therapeutics




compound 15 | NaPi2b

NaPi2b inhibitor
preclinical (hyperphosphatemia)
in-house compound screen + optimization
J. Med. Chem.
Kyowa Kirin Co., Ltd.




DS-3801b | GPR38

GPR38 agonist
Ph. I candidate for chronic constipation
from previously disclosed GPR38 agonists
Bioorg. Med. Chem. Lett.
Daiichi Sankyo Co., Ltd.



LEO 134310 | GR

glucocorticoid receptor agonist
Ph. I candidate for psoriasis
dual-soft drug
Sci. Rep.
LEO Pharma A/S



ATA-101 | α -7 nAChR

alpha-7 nicotinic receptor agonist
Ph. II candidate for chronic cough
drug repurposing
J. Pharmacol. Exp. Ther.
Johns Hopkins